(0.26%) 5 144.75 points
(0.14%) 38 496 points
(0.40%) 17 918 points
(-0.01%) $83.84
(0.36%) $1.930
(-0.02%) $2 346.80
(0.44%) $27.66
(2.49%) $945.05
(-0.19%) $0.933
(-0.34%) $10.99
(-0.34%) $0.798
(1.31%) $93.08
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 8.08%
@ $21.78
发出时间: 15 Feb 2024 @ 02:47
回报率: 4.39%
上一信号: Feb 14 - 22:30
上一信号:
回报率: -1.94 %
Live Chart Being Loaded With Signals
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics...
Stats | |
---|---|
今日成交量 | 143 698 |
平均成交量 | 396 116 |
市值 | 964.47M |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-1.260 ) 2024-05-02 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.47 |
ATR14 | $0.0370 (0.16%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 12 000 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 24 000 | Share Option (Right to Buy) |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
2024-04-18 | Baker Bros. Advisors Lp | Buy | 0 | American Depositary Shares |
INSIDER POWER |
---|
72.48 |
Last 94 transactions |
Buy: 1 498 500 | Sell: 230 741 |
音量 相关性
Bicycle Therapeutics PLC 相关性 - 货币/商品
Bicycle Therapeutics PLC 财务报表
Annual | 2023 |
营收: | $26.98M |
毛利润: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2023 |
营收: | $26.98M |
毛利润: | $20.40M (75.64 %) |
EPS: | $-5.08 |
FY | 2022 |
营收: | $14.46M |
毛利润: | $10.78M (74.51 %) |
EPS: | $-3.80 |
FY | 2021 |
营收: | $11.70M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bicycle Therapeutics PLC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。